One-Shot gene therapy aims to permanently lower heart disease risk
NCT ID NCT06451770
Summary
This early-stage study is testing the safety of a new, one-time gene-editing treatment called VERVE-201. It is designed for people with dangerously high cholesterol and triglycerides that don't respond well to standard medications. The treatment works by editing a gene in the liver to lower the levels of 'bad' fats in the blood long-term.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTRIGLYCERIDEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Study Center
RECRUITINGAdelaide, Australia
-
Clinical Study Center
RECRUITINGMelbourne, Australia
-
Clinical Study Center
RECRUITINGChicoutimi, Canada
-
Clinical Study Center
RECRUITINGMontreal, Canada
-
Clinical Study Center
RECRUITINGToronto, Canada
-
Clinical Study Center
RECRUITINGCape Town, South Africa
-
Clinical Study Center
RECRUITINGJohannesburg, South Africa
-
Clinical Study Center
RECRUITINGLiverpool, United Kingdom
-
Clinical Study Center
RECRUITINGLondon, United Kingdom
-
Clinical Study Center
RECRUITINGManchester, United Kingdom
Conditions
Explore the condition pages connected to this study.